PLx Pharma Completes $71M Underwritten Public Offering of Common Stock

The Firm represented PLx Pharma Inc., a late-stage specialty pharmaceutical company, in its underwritten registered public offering of shares of common stock, worth approximately $71 million, on the Nasdaq Capital Market.  PLx Pharma plans to use the net proceeds from the offering for general corporate purposes, including potential additions to working capital and capital expenditures, which also includes launching its new and recently FDA approved drug Vazalore, the first-ever liquid-filled aspirin capsule. The underwriters of the public offering were Raymond James & Associates, Inc. and Oppenheimer & Co. Olshan partner Robert Friedman represented PLx Pharma.